TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06110585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: The Intermittent Theta Burst Stimulation (iTBS) protocol will be used. This protocol involves bursts of stimulation at the theta frequency range, approximately 5 to 8 Hz. The specific combination utilized combines bursts of pulses at a frequency of 50 Hz, triggered at a rate of 5 Hz. Thus, a burst of 3 pulses is delivered with intervals of 20 ms between them, and this burst is repeated at intervals of 200 ms (i.e., 5 bursts per second). Every second, 15 pulses are delivered.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A stimulator with an arm containing a non-functional replica of the stimulation coil will be utilized. The application procedures will be identical to those of the active group, except that the device simulating the stimulation coil will not generate a magnetic field, only producing sound cues mimicking a stimulus.
Study: NCT05366556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The patient, whose blood will be drawn, will be asked to wear virtual reality glasses after sitting in the blood collection chair. One minute before the start of the blood collection process, Nature Hiking will be watched from the virtual reality. Meanwhile, the researcher will complete the preparations for blood collection and will start the blood collection process. It is thought that the blood collection process takes 2-3 minutes on average. During this period, virtual reality will be applied. While blood is being drawn from the patient, the researcher will assess the patient's level of pain with the VAS during the procedure. After the blood draw is completed, the virtual reality glasses will be removed. Then, the patient will be taken to the waiting area and the state anxiety scale will be applied.
Study: NCT04905654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study: NCT06530017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ingested, Space Occupying hydrogel capsules
Description: During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
Study: NCT06577376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
Study: NCT04905654

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: To investigate the role of levcromakalim compared with placebo in migraine with aura patients
Study: NCT06530017

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: During the treatment period (24 weeks after enrollment), Subjects should take four (4) capsules (Ingested, Space Occupying hydrogel capsules or placebo) with water every day 10\~20 minutes before lunch and dinner, and drink at least 500ml of water
Study: NCT04445805

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Description: Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, cognitive therapy, and relaxation. Treatment will be delivered via telemedicine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal-enhanced Behavioral Therapy for Insomnia
Description: Consists of 6 prenatal 60-min sessions and 6 monthly postnatal sessions on sleep education, sleep restriction, stimulus control, and metacognitive exercises. Treatment will be delivered via telemedicine.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Will include education on sleep, circadian rhythms, and good sleep hygiene in addition to self-monitoring with sleep diaries.
Study: NCT04968938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midomafetamine
Description: 80 mg or 120 mg midomafetamine HCl followed by a 40 mg supplement dose
Study: NCT06429098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT04968938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Manualized therapy
Study: NCT05976074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: The smartwatch will collect data including accelerometry, heart rate, activity, move time, exercise time, stand time, steps, walking and running distance, heart rate variability, respiratory rate, six-minute walk, and flights climbed. During sleep, the smartwatch will collect daily nighttime physiologic data such as time in bed, average sleep time, sleep efficiency, wake after sleep onset, nocturnal heart rate, and nocturnal respiratory rate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainRISE app
Description: The app will play a prerecorded video, which will walk participants through tasks which include holding your arms in different postures, repeating different vowel sounds and phrases as prompted, and tracing different patterns on the phone screen. The tasks are video and audio recorded while being completed. Completing the tremor assessment tasks will take about 10 minutes.
Study: NCT04933578

Intervention type: BEHAVIORAL
Intervention: Dental anxiety scales
Description: * The Faces Version of Modified Child Dental Anxiety Scale (MCDASf), which is a psychometric dental anxiety scale for children with eight questions, was used to determine the dental anxiety levels of the children. The scores of each question are represented by varying cartoon faces according to emotions ranging from 1 'relaxed' to 5 'very anxious'. The total scores range from 8 to 40. The scores were categorized as not anxious (\>9), slightly anxious (9-16), fairly anxious (17-24), very anxious (25-32), and extremely anxious (33-40).~* the Modified Dental Anxiety Scale (MDAS) was administered to parents, differently from children. The MDAS has five questions. The scores of each question range from 1 'relaxed' to 5 'very anxious.' The total score ranges from 5 to 25.
Study: NCT05498376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pacemaker DDD
Description: Implantation of a conventional cardiac pacemaker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leadless pacemaker Micra AV
Description: Implantation of a leadless cardiac pacemaker
Study: NCT05023252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile application
Description: VetThrive is a mobile smartphone application that monitors and transmits mobile sensor and utilization data. This app is deployed in Veteran patients who passively self-track their behaviors and psychiatric symptoms.
Study: NCT06368245

Intervention type: PROCEDURE
Intervention: long-segment posterior TL instrumented fusion
Description: long-segment posterior TL instrumented fusion with either supplementary rod constructs or dual-rod constructs.

Intervention type: PROCEDURE
Intervention: long-segment posterior TL instrumented fusion
Description: long-segment posterior TL instrumented fusion with either supplementary rod constructs or dual-rod constructs.
Study: NCT05610176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amvia Sky pacemaker or CRT-P device
Description: Subjects with an indication for a pacemaker or CRT-P device will be implanted with an Amvia Sky device of the Amvia/Solvia pacemaker family according to standard pacemaker implantation procedures. Device programming will be done according to the medical needs of the subjects.
Study: NCT04662541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Integrated Health (MIH)
Description: MIH leverages paramedics in the community and telemedicine (technology-enabled communication for health purposes) to provide medical care to heart failure patients in the home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transitions of care coordinator (TOCC)
Description: The TOCC group will receive a follow-up phone call shortly after discharge in which the patient is assessed and connected to clinical and social services as needed and patient education is reinforced.
Study: NCT06535750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants were randomly divided into two treatment groups. There are 10 patients in each group. The patients in the control group received a standard treatment programme, while the patients in the experimental group received strengthening exercises with theraband in addition to the standard treatment programme. Treatment sessions for both groups lasted 50-55 minutes and were performed three days a week. Details of the study groups are given below.
Study: NCT04733560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal nerve block
Description: Vaginally administered pudendal nerve block of 10ml 0.25% Bupivacaine prior to making any surgical incisions.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Pudendal nerve block
Description: Vaginally administered pudendal nerve block of 10ml Normal Saline prior to making any surgical incisions.
Study: NCT06577376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker
Study: NCT04733560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injectable Product
Description: Used for pudendal nerve block in the intervention arm
Study: NCT06577376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib tablets
Description: A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib tablets
Description: A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib tablets
Description: A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmitinib tablets
Description: A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
Study: NCT06577376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposomes
Description: A chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel or docetaxel or irinotecan
Description: Paclitaxel or docetaxel or irinotecan is used as a control.
Study: NCT06648889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Cohort 1: All patients will receive two cycles of induction therapy with standard chemotherapy, Bortezomib and Isatuximab. Isatuximab maintenance may be administered in patients with CR until SCT, progression/relapse, unacceptable toxicity, physicians' decision to change treatment or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Cohort 2: All patients will receive at least one cycle with Isatuximab. Each cycle will be 4 weeks in duration. Isatuximab will be administered until SCT, hematologic relapse including extramedullary, unacceptable toxicity, physicians' decision, or withdrawal of consent.
Study: NCT06647953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT06091774

Intervention type: DEVICE
Intervention: CHD therapy through iATROS medical device
Description: The intervention to be carried out in the treatment group is the use of the therapy control for the treatment of CHD played out via the iATROS medicine product. Patients will receive a suitable and medical device certified measuring device for recording vital parameters. The iATROS app is downloaded to the patient's smartphone and the app is activated by entering a code that identifies the user as a participant in the study. When using the app for the first time, the patient is guided through the first steps of using the app and asked to transfer his or her health data to the app. The therapy control by means of the medication product takes place over the entire duration of the study.
Study: NCT05394142

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator arm with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 7.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 7.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 7.5 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 50 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 50 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg/day
Study: NCT04667117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: 2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: 2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine
Description: 2020-2021, 2021-2022, or 2022-2023 inactivated quadrivalent influenza vaccine. Participants received the vaccine within 9 calendar days after the Screening Visit, before the Week 0 Visit occurred.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Auto-injector containing 20 mg ofatumumab (20 mg/0.4mL) for subcutaneous (s.c.) administration.~* Participants in Cohort 1 received loading doses of 20 mg ofatumumab s.c. at Weeks 2, 3, and 4 in the Investigational Period. In the open-label Extension Period, they administered the first dose of ofatumumab at Week 6 and continued monthly dosing until the final dose at Week 26. Novartis supplied participants in Cohort 1 with ofatumumab treatment.~* Participants in Cohort 2 continued on their commercially prescribed ofatumumab treatment during the Investigational Period. In the open-label Extension Period, they continued to administer ofatumumab monthly until the final dose at Week 28. Cohort 2 participants in the extension could have either remained on their prescribed ofatumumab or switched to study supplied ofatumumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iDMT
Description: Participants in Cohort 3 continued on their commercially prescribed injectable disease modifying therapy (iDMT) during the Investigational Period.
Study: NCT04937374

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehmannia glutinosa leaf extract
Description: One capsule to be taken after breakfast.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose (MCC)
Description: One capsule to be taken after breakfast.
Study: NCT03832127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fludarabine
Description: Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
Study: NCT05800392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEC103
Description: The intervention is composed by two medications: An active sublingual pill and an active oral one.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DEC103
Description: The intervention is composed by two medications: A placebo sublingual pill and an placebo oral one.
Study: NCT06647953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Given IV
Study: NCT05771831

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes®
Description: The intervention with TBX® is to be administered as an intravenous infusion as hemostatic blood product as part of the Massive Transfusion Protocol (MTP).
Study: NCT06078085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation program
Description: The rehabilitation program is created by a physical therapist
Study: NCT05771831

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard platelet concentrate
Description: The administration of standard platelets is administrated, as part of the Massive Transfusion Protocol (MTP).